| 贾梦荻,朱雪珂.前列地尔联合胰激肽原酶在糖尿病足患者中的应用研究[J].中国烧伤创疡杂志,2025,(2):105~109. |
| DOI： |
| 中文关键词: 前列地尔 胰激肽原酶 糖尿病足 踝肱指数 足背动脉流速 |
| 英文关键词:Alprostadil Pancreatic kininogenase Diabetic foot Ankle-brachial index Dorsal artery velocity |
| 基金项目: |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 【摘要】 目的 分析探讨前列地尔与胰激肽原酶联合在糖尿病足 (DF) 患者中的应用效果。 方法 选取2022 年 4 月至 2023 年 4 月河南科技大学第一附属医院收治的 108 例 DF 患者作为研究对象, 按照不同治疗方法将其分为前列地尔组 (36 例)、胰激肽原酶组 (36 例) 和联合组 (36例)。 前列地尔组患者行前列地尔治疗, 胰激肽原酶组患者行胰激肽原酶治疗, 联合组患者行前列地尔+胰激肽原酶联合治疗, 对比观察 3 组患者踝肱指数、足背动脉流速、血糖与血脂指标、临床疗效以及不良反应发生情况。结果 治疗4周后,联合组患者踝肱指数、足背动脉流速均明显大于前列地尔组和胰激肽原酶组 (踝肱指数: q = 9.247、8.703, P 均<0.001; 足背动脉流速: q = 12.081、11.149, P均<0.001); 3 组间空腹血糖、糖化血红蛋白水平无明显差异 (F= 0.135、0.125, P=0.874、0.883); 联合组患者甘油三酯、胆固醇水平均明显低于前列地尔组和胰激肽原酶组 (甘油三酯: q =3.772、4.401, P= 0.024、0.007; 胆固醇: q = 3.417、4.100, P = 0.046、0.013); 联合组患者治疗总有效率明显高于前列地尔组和胰激肽原酶组 ( χ2 = 7.432、5.063, P = 0.006、0.024)。 治疗期间, 3 组患者不良反应发生率无明显差异 (χ2 = 0.270, P= 0.874)。结论 与单纯应用前列地尔、胰激肽原酶相比, 两者联合应用更能明显提高 DF 患者足背动脉流速、改善脂质代谢, 临床疗效更显著。 |
| 英文摘要: |
| 【Abstract】 Objective To analyze the clinical efficacy of application of alprostadil combined with pancreatic kininogenase in patients with diabetic foot (DF). Methods 108 DF patients admitted to The First Affiliated Hospital of Henan University of Science and Technology from April 2022 to April 2023 were enrolled as the research subjects and divided into the alprostadil group (n = 36), the pancreatic kininogenase group (n = 36), and the combined group (n = 36) according to different treatment methods. Patients in the alprostadil group were treated with alprostadil, patients in the pancreatic kininogenase group were treated with pancreatic kininogenase, and patients in the combined group were treated with alprostadil plus pancreatic kininogenase. Ankle-brachial index, dorsal artery velocity, blood glucose and lipid indexes, clinical efficacy, and the occurrence of adverse reactions were compared among the three groups. Results After 4 weeks of treatment, the ankle-brachial index and dorsal artery velocity of patients in the combined group were significantly greater than those in the alprostadil group and the pancreatic kininogenase group (ankle-brachial index: q = 9.247 and 8.703, both P<0.001; dorsal artery velocity: q = 12.081 and 11.149, both P<0.001). There were no significant differences in fasting blood glucose and glycated hemoglobin levels among the three groups ( F = 0.135 and 0.125, P = 0.874 and 0.883). Triglyceride and cholesterol levels of patients in the combined group were significantly lower than those in the alprostadil group and the pancreatic kininogenase group (triglycerides: q = 3.772 and 4.401, P = 0.024 and 0.007; cholesterol: q = 3.417 and 4.100, P = 0.046 and 0.013). The total effective rate of treatment in the combined group was significantly higher than that in the alprostadil group and the pancreatic kininogenase group ( χ2 = 7.432 and 5.063, P = 0.006 and 0.024). There were no significant differences in the incidence of adverse reactions among the three groups during the treatment period (χ2 = 0.270, P= 0.874). Conclusion Compared with the application of alprostadil or pancreatic kininogenase alone, the combination application of alprostadil and pancreatic kininogenase can significantly increase dorsal artery velocity and improve the lipid metabolism in patients with DF, presenting better clinical efficacy. |
|
|
|
|
